1702. Platelet Counts in Contezolid Complicated Skin and Soft Tissue Infection Phase 2 and Phase 3 Clinical Trials

BACKGROUND: Contezolid (CZD; MRX-I) is a novel oral (PO) oxazolidinone with potent activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococccus (VRE). Nonclinical and Phase 1 (Ph1) clinical data indicate CZD may cause l...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Edward, Yang, Huahui, Yuan, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752688/
http://dx.doi.org/10.1093/ofid/ofac492.1332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752688/
http://dx.doi.org/10.1093/ofid/ofac492.1332

Ejemplares similares